APA (7th ed.) Citation

Irving, A., Petrie, D., Harris, A., Fanning, L., Wood, E. M., Moore, E., . . . McQuilten, Z. K. (2026). A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data. PharmacoEconomics, 44(1), 83. https://doi.org/10.1007/s40273-025-01554-4

Chicago Style (17th ed.) Citation

Irving, Adam, et al. "A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data." PharmacoEconomics 44, no. 1 (2026): 83. https://doi.org/10.1007/s40273-025-01554-4.

MLA (9th ed.) Citation

Irving, Adam, et al. "A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data." PharmacoEconomics, vol. 44, no. 1, 2026, p. 83, https://doi.org/10.1007/s40273-025-01554-4.